Analyst Price Targets — HRMY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 23, 2026 11:37 am | — | Deutsche Bank | $31.00 | $29.16 | TheFly | Harmony Biosciences downgraded to Hold from Buy at Deutsche Bank |
| February 19, 2026 12:17 pm | — | Mizuho Securities | $50.00 | $35.28 | TheFly | Harmony Biosciences price target raised to $50 from $46 at Mizuho |
| February 11, 2026 12:28 pm | Youn Shim | UBS | $46.00 | $37.93 | TheFly | Harmony Biosciences assumed at Neutral from Buy at UBS |
| January 8, 2026 12:54 pm | — | Truist Financial | $45.00 | $37.55 | TheFly | Harmony Biosciences price target lowered to $45 from $48 at Truist |
| December 1, 2025 11:56 am | — | Mizuho Securities | $46.00 | $35.29 | TheFly | Harmony Biosciences price target raised to $46 from $39 at Mizuho |
| November 24, 2025 9:40 am | Andreas Argyrides | Oppenheimer | $62.00 | $34.31 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Harmony Biosciences Holdings Inc. (HRMY) Post Mgmt Meet |
| October 29, 2025 12:50 pm | — | Mizuho Securities | $36.00 | $29.64 | TheFly | Harmony Biosciences price target raised to $36 from $35 at Mizuho |
| October 15, 2025 11:07 am | — | UBS | $43.00 | $26.85 | TheFly | Harmony Biosciences price target lowered to $43 from $50 at UBS |
| September 25, 2025 10:11 am | — | H.C. Wainwright | $55.00 | $27.04 | TheFly | Harmony Biosciences price target lowered to $55 from $70 at H.C. Wainwright |
| July 10, 2025 9:08 am | Corinne Johnson | Goldman Sachs | $33.00 | $34.33 | TheFly | Harmony Biosciences resumed with a Neutral at Goldman Sachs |
Latest News for HRMY
Harmony Biosciences Holdings, Inc. (HRMY) Q4 2025 Earnings Call Transcript
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.38 per share, missing the Zacks Consensus Estimate of $0.84 per share. This compares to earnings of $0.85 per share a year ago.
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced earnings with reported revenue of $243.8 million for Q4 2025, representing 21% year-over-year revenue growth for WAKIX®. For the full year 2025, the company generated $868.5 million in net product revenue, reflecting continued commercial strength as evidenced by six consecutive years of revenue growth and…
Value stocks are back in focus as markets remain steady. HRMY, TRIP, AES and CNXC screen cheap on P/CF, offering growth and cash flow strength.
AES joins four other low P/B stocks that screen for value, growth and liquidity, offering investors undervalued picks to watch in February.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for HRMY.
U.S. House Trading
No House trades found for HRMY.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.